The risk of mortality in patients with psoriasis: Results from a population-based study

Archives of Dermatology

Volumn 143, Issue 12, 2007, Pages 1493-1499

  Gelfand, Joel M ^a   Troxel, Andrea B ^a   Lewis, James D ^a   Kurd, Shanu Kohli ^a   Shin, Daniel B ^a   Wang, Xingmei ^a   Margolis, David J ^a   Strom, Brian L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTHRITIS; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSORIASIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC THERAPY; UNITED KINGDOM;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PSORIASIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 37249004404     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.12.1493     Document Type: Article

References (33)

1. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-139.
2. Gelfand JM, Wang X, Qing L, et al. Epidemiology and treatment patterns of psoriasis in the General Practice Research Database (GPRD) [abstract]. Pharmacoepidemiol Drug Saf. 2005;14:S23.
3. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141(12):1527-1534.
4. Neimann AL, Porter SB, Gelfand JM. Epidemiology of psoriasis. Expert Rev Dermatol. 2006;1(1):63-75.
5. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol. 2003;139(11):1425- 1429.
6. Pearce DJ, Lucas J, Wood B, Chen J, Balkrishnan R, Feldman SR. Death from psoriasis: representative US data. J Dermatolog Treat. 2006;17(5):302-303.
7. Kuitunen T, Malmström J, Palva E, Pettersson T. Pancytopenia induced by low-dose methotrexate: a study of the cases reported to the Finnish Adverse Drug Reaction Register from 1991 to 1999. Scand J Rheumatol. 2005;34(3):238-241.
8. Roth PE, Grosshans E, Bergoend H. Psoriasis: development and fatal complications [in French]. Ann Dermatol Venereol. 1991;118(2):97-105.
9. Zachariae H, Søgaard H, Heickendorff L. Methotrexate-induced liver cirrhosis: clinical, histological and serological studies - a further 10-year follow-up. Dermatology. 1996;192(4):343-346.
10. Lindega° rd B. Mortality and causes of death among psoriatics. Dermatologica. 1989;179(2):91-92.
11. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19(3):225-230.
12. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol. 1999;135(12):1490-1493.
13. Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients [published correction appears in J Invest Dermatol. 1989;92(2):300]. J Invest Dermatol. 1988;91(3):197-201.
14. Kelsey JL, Whittemore AS, Evans AS, Thompson WD. Methods in Observational Epidemiology. 2nd ed. New York, NY: Oxford University Press; 1996.
15. Gelfand JM, Dattani H, Margolis DJ. The UK General Practice Research Database. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. New York, NY: John Wiley & Sons Inc; 2005:337-346.
16. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302(6779):766-768.
17. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the General Practice Research Database. Pharmacotherapy. 2003;23(5):686-689.
18. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537-1541.
19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
20. Cox D. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
21. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol. 1996;135(4):533-537.
22. Deaths [Tables 6.1-6.3]. Health Stat Q. Summer 2004;(22):50-53.
23. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573-577.
24. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-1741.
25. Card TR, Solaymani-Dodaran M, Hubbard R, Logan RF, West J. Is an internal comparison better than using national data when estimating mortality in longitudinal studies? J Epidemiol Community Health. 2006;60(9):819-821.
26. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241-249.
27. Chalmers RJ, Griffiths CE. Resetting the research agenda for psoriasis. J Invest Dermatol. 2003;120(5):ix-x.
28. Gelfand JM, Shin DB, Neimann AL,WangX, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126(10):2194-2201.
29. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-835.
30. Boffetta P, Gridley G, Lindelöf B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol. 2001;117(6):1531-1537.
31. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum. 2000;43(1):14-21.
32. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis [published correction appears in J Am Acad Dermatol. 2005;52(4):670]. J Am Acad Dermatol. 2005;52(2):262-267.
33. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359(9313):1173-1177.